Concord Drugs Ltd — Others, 31-07-2025: AGM/EGM

Concord Drugs Limited held an Extraordinary General Meeting (EGM) where members approved key resolutions. These include an increase in the company's Authorised Share Capital, which is crucial for future growth. Shareholders also greenlit the issuance of Equity Shares and Convertible Warrants on a preferential basis. These approvals will enable the company to strengthen its capital base and potentially fund strategic initiatives, benefiting long-term stakeholders.